Pages

July 05, 2012

Rapamycin and Metformin Could Work Better Together for Life Extension Without Side Effects

Rejuvenation Research Journal - Dissecting Mammalian Target of Rapamycin to Promote Longevity

Treatment with rapamycin, an inhibitor of mammalian target of rapamycin complex 1 (mTORC1) can increase mammalian life span. However, extended treatment with rapamycin results in increased hepatic gluconeogenesis concomitant with glucose and insulin insensitivity through inhibition of mTOR complex 2 (C2). Genetic studies show that increased life span associated with mTORC1 inhibition can be at least partially decoupled from increased gluconeogenesis associated with mTORC2 inhibition. Adenosine monophosphate kinase (AMPK) agonists such as metformin, which inhibits gluconeogenesis by downregulating expression of glucose-6-phosphatase and phosphoenolpyruvate carboxykinase, might be expected to block the glucose dysmetabolism mediated by rapamycin. The search for inhibitors of the mTORC1 component Raptor may prove a productive approach to create a better mTOR inhibitor.

Fightaging has coverage about how the diabetes drug Metformin could prevent the negative side effects of Rapamycin.





If you liked this article, please give it a quick review on ycombinator or StumbleUpon. Thanks
blog comments powered by Disqus